证券日报网讯 2月26日，国际医学在互动平台回答投资者提问时表示，近年来，公司整体医疗业务保持 了稳定的发展态势，学科实力持续增强，营业收入稳步增长，但营业收入规模尚未能覆盖运营成本和期 间费用。根据2025年业绩预告，公司受市场波动、DRG支付政策改革等行业动态调整影响，营业收入 同比有所下降。公司采取调整业务结构，实施降本增效等措施并持续改善经营成效，第四季度亏损幅度 收窄。 （编辑 丛可心） ...

针对上述提问，国际医学回应称："您好，感谢您对公司的关注。公司将根据股东会确立的发展战略， 积极采取各项措施，以差异化策略构建竞争优势，努力实现经营业绩的改善提升。谢谢！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 有投资者在互动平台向国际医学提问："留给国际医学的时间确实不多了。年报即将披露，股价在5元上 下徘徊，大股东质押比例逼近80%，短期债务压顶——每一条都是悬在头顶的剑。投资者不是没耐心， 而是经不起反复'黎明前最黑暗'的安慰。医疗是长周期行业，但长周期不等于无期限烧钱，更不等于用 股东的钱为管理试错买单。" ...

Group 1 - The company, International Medicine (000516), responded to investor inquiries on February 13, indicating that any significant information regarding the company should be based on official disclosures [1]

Core Viewpoint - International Medical (000516) has shown a decline in revenue and profit for the first three quarters of 2025, indicating potential challenges in its business operations and financial health [2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 2.995 billion yuan, a year-on-year decrease of 16.94% [2]. - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year [2]. - The net profit after deducting non-recurring items was -312 million yuan, a decline of 41.94% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 961 million yuan, a decrease of 18.95% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -129 million yuan, a significant drop of 234.24% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -123 million yuan, down 52.03% year-on-year [2]. - The company's debt ratio stood at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan [2]. - The gross profit margin was 6.59% [2]. Market Activity - As of February 10, 2026, the stock closed at 4.96 yuan, with an increase of 0.4% [1]. - The turnover rate was 1.55%, with a trading volume of 341,700 hands and a transaction amount of 169 million yuan [1]. - On February 10, the net inflow of main funds was 15.2399 million yuan, accounting for 8.99% of the total transaction amount [1]. - Retail investors experienced a net outflow of 280,100 yuan, representing 0.17% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, two institutions have given ratings for the stock, both recommending an increase in holdings [3]. - The average target price set by institutions over the past 90 days is 5.5 yuan [3].

近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 证券之星消息，截至2026年2月9日收盘，国际医学(000516)报收于4.94元，上涨0.82%，换手率1.28%， 成交量28.17万手，成交额1.39亿元。 2月9日的资金流向数据方面，主力资金净流入285.01万元，占总成交额2.05%，游资资金净流出632.9万 元，占总成交额4.55%，散户资金净流入347.88万元，占总成交额2.5%。 该股最近90天内共有2家机构给出评级，增持评级2家；过去90天内机构目标均价为5.5。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301 ...

Core Viewpoint - The collaboration between Shanghai Jiao Tong University School of Medicine Hainan International Medical Center and Hainan Middle School aims to enhance the understanding and interest of Hainan youth in medicine and cutting-edge science through various educational initiatives [1] Group 1: Educational Initiatives - The center will establish an "Academician Lecture Hall" and conduct popular science lectures to engage students [1] - A research mentor program will be implemented to expose students to scientific innovation during critical growth stages [1] - The initiative includes multiple high-quality projects such as "Zhenduan Lecture," "Summer and Winter Research Camps," and "Academic Guidance Program" to provide advanced scientific education [1] Group 2: Talent Development - The collaboration aims to facilitate the early discovery and systematic cultivation of top innovative talents in Hainan [1] - The program is designed to instill a sense of scientific spirit and innovation among local students [1]

Core Viewpoint - The company is facing questions from investors regarding its declining performance and the effectiveness of its management team, particularly under the leadership of Shi Jin [1]. Group 1: Management Response - The company asserts that its management team possesses extensive operational experience, which supports the company's standardized operations and efficient management [1]. - The company emphasizes its commitment to closely align with its development strategy to enhance operational management and drive high-quality growth [1]. - The management expresses confidence in their ability to continuously improve the company's value [1].

Core Viewpoint - The company plans to adjust its business structure and implement cost reduction and efficiency improvement measures by 2025, aiming to narrow its losses in the fourth quarter [1] Group 1: Business Strategy - The company will focus on refined operations to enhance operational quality and efficiency [1] - A differentiated strategy will be employed to build competitive advantages and increase service added value [1] Group 2: Market Opportunities - The company aims to align with the national aging strategy and seize opportunities in the "silver economy" by developing smart healthcare projects [1] Group 3: Brand Development - The company intends to create an excellent medical service system and establish a significant industry brand [1]

Core Viewpoint - The company maintains a stable financial condition with manageable debt risk despite a decrease in cash reserves and an increase in the debt-to-asset ratio [1] Group 1: Financial Performance - As of Q3 2025, the company reported a positive operating cash flow of 921 million [1] - The positive cash flow does not necessarily translate into an increase in cash reserves at the end of the period [1] Group 2: Debt Management - The company is actively managing its obligations, including payments to suppliers and equipment, which are not reflected in the operating cash flow [1] - The company perceives its debt risk as controllable and is focused on maintaining a healthy financial structure [1] Group 3: Fundraising Strategy - The company plans to raise 1 billion to support new business projects, aiming to avoid excessive use of operational funds and to optimize its capital structure [1] - The fundraising is aligned with the company's long-term development strategy [1]

Group 1 - The core viewpoint of the article is that the company is actively adjusting its business structure to enhance growth and meet market demands [1] - The company is focusing on sectors such as health care, medical beauty, rehabilitation, maternal and child services, assisted reproduction, and special needs services [1] - The company plans to establish specialized departments such as elderly care facilities, Huibin departments, and proton therapy to cater to market needs [1]